9 5 7 4 9
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
罗氟司特治疗哮喘-慢阻肺重叠的药理机制
Authors Zhang X, Chen Y, Fan L, Ye J, Fan J, Xu X, You D, Liu S, Chen X, Luo P
Received 9 February 2018
Accepted for publication 26 May 2018
Published 1 August 2018 Volume 2018:12 Pages 2371—2379
DOI https://doi.org/10.2147/DDDT.S165161
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Palas Chanda
Peer reviewer comments 3
Editor who approved publication: Professor Manfred Ogris
摘要： 哮喘-慢阻肺重叠（Asthma–COPD
overlap, ACO）是一种不完全阻塞性气道疾病，有着高发病率和死亡率，但是目前对 ACO 并没有明确的定义，也没有有效的干预措施。新发现的磷酸二酯酶-4（PDE-4）抑制剂罗氟司特（Roflumilast）在哮喘、慢性阻塞性肺疾病及 ACO 的治疗中均显示出初步的疗效。然而，罗氟司特的作用机制尚不明了，还没有系统综述对其进行阐释。明确罗氟司特确切的药理机制不仅将指导临床医生用药，还将指导标准化治疗及治疗指南。因此，我们系统总结了罗氟司特治疗 ACO 的药理机制，望为临床应用罗氟司特治疗 ACO 提供参考。
关键词：哮喘-慢阻肺重叠，罗氟司特，磷酸二酯酶-4 抑制剂，机制
